News Article | May 15, 2017
National industry-leading healthcare marketing awards competition Aster Awards has recognized Trajectory with two GOLD awards for its Virtual Reality healthcare marketing program for Reading Health System and its "We Vs. C" cancer services foundation/fundraising program for RWJ University Hospital Hamilton. READING HEALTH SYSTEM VIRTUAL REALITY As part of Trajectory’s integrated healthcare campaign promoting the opening of Reading HealthPlex for Advanced Surgical & Patient Care, the agency developed a Virtual Tour video for multiple pre-launch marketing purposes as well as a fully immersive Virtual Reality experience for special applications (i.e. use at events for personal demonstrations with special glasses). Since the facility was still under construction, the Virtual Tour Video and Virtual Reality Experience provided varied audiences (community, physicians and medical practitioners, key stakeholders and influencers) with a preview of what the completed facility had to offer – in a way that was as unique, differentiating and compelling as the facility itself. RWJ UNIVERSITY HOSPITAL HAMILTON (RWJBARNABAS HEALTH) PROJECT WE VS. C This unique two-year healthcare marketing cause campaign combines the healing effects of song, dance, music and the arts – to highlight and support RWJ University Hospital Hamilton (RWJBarnabas Health) Cancer Services program. Fundraising efforts will contribute to a vital $8.5 million, two-year project geared exclusively for enhancements to RWJ Hamilton’s comprehensive cancer program. Given the crowded market filled with many Breast Cancer/fundraising initiatives, the program required an impactful and compelling brand identity, both visual and messaging, to target both the public and potential donors. Trajectory deliverables included program name and logo to umbrella the overall two-year project, long-form writing of brochure materials and solicitation materials for outreach and promotion, development of marketing roadmap and all aspects of launch marketing materials. Success of "We Vs. C" will be measured through funds raised to save more lives through prevention, detection, treatment and ongoing support. For more information about Trajectory – brand consultancy/marketing agency dedicated to creating the momentum for brands to thrive in today's health + wellness economy – visit http://www.trajectory4brands.com.
News Article | October 28, 2016
Western Connecticut Health Network (WCHN) has named internationally known physician-scientist, John A. Martignetti, MD, PhD, an expert in human genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai, as the Network Director of the Laboratory for Translational Research at the WCHN Biomedical Research Institute. Under this collaboration, Dr. Martignetti’s well-established bedside to bench cancer research methodology will be extended to patients at Danbury, Norwalk and New Milford hospitals leading to more personalized and successful therapeutic strategies. He will work closely with the oncology physicians and research scientists across WCHN to build on their nationally recognized efforts. Working alongside new colleagues at WCHN, Dr. Martignetti will continue to explore precision medicine strategies to 1) advance the care and treatment of patients with gynecologic cancer and 2) establish effective biomarkers to enable reliable disease surveillance leading to more predictable care pathways. He will also pursue development of novel therapeutics while studying the genetics of hereditary ovarian and breast cancer. "WCHN offers innovative cancer care that rivals any center in the country," Dr. Thomas Rutherford, WCHN Network Director for Cancer Services said. "As a practitioner, it is very exciting to be working with someone of Dr. Martignetti’s reputation and devotion as we collaborate on new ways to beat cancer. I am looking forward to integrating the excellent cancer programs, services, and providers in our cancer care team at WCHN with the exciting research Dr. Martignetti has underway so our patients are served by the most personalized medicine possible." "We are thrilled to have Dr. Martignetti join the WCHN family and lead our Translational Research team," said WCHN President and CEO Dr. John Murphy. "John has an outstanding reputation for both his clinical and research experience, and he is so deeply committed to solving the needs of those suffering from cancer. His vision and leadership will enhance the great care provided by an excellent cancer team in place today. Working with Dr. Tom Rutherford and our oncology team, his guidance, as we transform cancer care for our communities, will be invaluable." “I am excited to join the very dedicated and committed cancer team at WCHN and look forward to this partnership that is aimed at revolutionizing oncology research and patient care,” said Dr. Martignetti, MD, PhD, Associate Professor of Genetics and Genomic Sciences, Oncological Sciences, Pediatrics, Obstetrics, Gynecology and Reproductive Science at the Icahn School of Medicine at Mount Sinai. He earned his BA from Columbia College, Columbia University and was awarded his MPhil in molecular biology from Cambridge University. He received his MD and MD, PhD from the Icahn School of Medicine at Mount Sinai in New York and is widely published in the fields of Cancer Genetics, Gene Discovery, Genomics, and Molecular Biology. About Western Connecticut Health Network Oncology Services Western Connecticut Health Network is the region’s leading provider of cancer care services. Danbury Hospital Praxair Cancer Center, New Milford Hospital Diebold Cancer Center and Norwalk Hospital Whittingham Cancer Center are nationally accredited as Comprehensive Care Programs by the American College of Surgeons (ACS). The Centers are the recipients of “Accreditation with Commendation” from the Commission on Cancer which recognizes cancer programs that strive for excellence in providing comprehensive, multidisciplinary quality care to cancer patients. At Western Connecticut Health Network, our patients and their families receive an exceptional level of care, support and access to clinical trials in a compassionate environment, close to home, by our multidisciplinary care team of experienced medical oncologists, radiation oncologists, surgical oncologists, pathologists, radiologists, oncology nurses along with our oncology nurse navigators and other specialists with advanced training. Research at Western Connecticut Health Network Research and innovation at the WCHN includes the WCHN Biomedical Research Institute where the focus is on cancer and Lyme disease research. This work is complimented by our Global Health, Harold A. Spratt Center for Simulation and Clinical learning, our clinical trials and clinical outcomes and health services research-all funded by generous donors who recognize the life- changing and life-saving work underway. For more information contact the WCHN Foundation. About Western Connecticut Health Network Western Connecticut Health Network is the region's premier, patient-centered health care organization serving residents of Western Connecticut and adjacent New York. With this recent affiliation, the organization is now anchored by three nationally recognized hospitals, Danbury Hospital, New Milford Hospital and Norwalk Hospital, as well as their affiliated organizations. In addition to the three hospitals, the continuum of care offered includes numerous medical practices and sub-specialties across the region, home health care services, a nationally renowned biomedical research institute, the Danbury Hospital & New Milford Hospital Foundation, the Norwalk Hospital Foundation and other affiliates. For more information, visit TheNewWCHN.org. Share your comments with us at Facebook.com/DanburyHospital; Facebook.com/NewMilfordHospital and/or Facebook.com/NorwalkHospital. # # #
Alexander M.,Peter MacCallum Cancer Center |
Bajel A.,Royal Melbourne Hospital |
Doecke C.,Royal Adelaide Hospital |
Doecke C.,University of South Australia |
And 15 more authors.
Internal Medicine Journal | Year: 2014
These consensus guidelines provide recommendations for the safe handling of monoclonal antibodies. Definitive recommendations are given for the minimum safe handling requirements to protect healthcare personnel. The seven recommendations cover: (i) appropriate determinants for evaluating occupational exposure risk; (ii) occupational risk level compared with other hazardous and non-hazardous drugs; (iii) stratification of risk based on healthcare personnel factors; (iv) waste products; (v) interventions and safeguards; (vi) operational and clinical factors and (vii) handling recommendations. The seventh recommendation includes a risk assessment model and flow chart for institutions to consider and evaluate clinical and operational factors unique to individual healthcare services. These guidelines specifically evaluated monoclonal antibodies used in the Australian cancer clinical practice setting; however, the principles may be applicable to monoclonal antibodies used in non-cancer settings. The guidelines are only applicable to parenterally administered agents. © 2014 Royal Australasian College of Physicians.
Lee A.V.,Barts and The London NHS Trust |
Bibby D.F.,Barts and The London NHS Trust |
Oakervee H.,Cancer Services |
Rohatiner A.,Cancer Services |
And 3 more authors.
Transplant Infectious Disease | Year: 2011
We report an outbreak of parainfluenza 3 virus involving 17 hematology-oncology patients on 2 hospital wards. Sequence analysis of clinical samples confirmed homology of strains for 16/17 patients and 1 healthcare worker. Epidemiological analysis of the outbreak supported the molecular data with nosocomial transmission of the same genetic strain as the cause of the outbreak. © 2011 John Wiley & Sons A/S.
Lim S.H.,Liverpool and Campbelltown Hospitals |
Lim S.H.,Ingham Institute for Applied Medical Research |
Lim S.H.,University of New South Wales |
Delaney G.P.,Ingham Institute for Applied Medical Research |
And 9 more authors.
PLoS ONE | Year: 2014
Purpose: There is a lack of information in ethnic minority groups with regard to presentation and treatment of early node-positive breast cancer. We carried out a retrospective study of patients referred to two tertiary cancer centers in South Western Sydney, both of which serve a high proportion of this ethnic minority population. Patients and methods: Women who had pathologically node-positive non-metastatic breast cancer (T1-3, N1-3, M0) diagnosed between 2003 and 2006 were studied, with variables of interest being tumor size, number of positive nodes, histological grade, hormone receptor status, age at diagnosis, country of birth and treatment. We compared the Asian and Western subgroups with regard to tumor characteristics, treatment and clinical outcomes. Results: A total of 652 eligible patients were identified, with a median follow-up of 6.1 years. Women with Asian backgrounds (n = 125, 20%) were significantly younger at presentation (48 years versus 55 years, p-value <0.0001) and more likely to undergo mastectomy (53% versus 39%, p-value 0.0009) and chemotherapy (86% versus 72%, p-value 0.0063) than their non-Asian counterparts. Tumor stage, grade and receptor status were not statistically different between these two groups. There were also no differences in disease-free survival and overall survival, with medians of 12.7 and 14.8 years respectively. Conclusion: Women of Asian background are younger at diagnosis, which may reflect population epidemiology and likely results in higher uptake of chemotherapy. Higher mastectomy rates may be influenced by cultural factors. Future research is warranted to investigate potential differences in tumor biology, psychosocial, economic and cultural factors. © 2014 Lim et al.
News Article | February 21, 2017
HERS Breast Cancer Foundation today announced a community awards gala to be held Saturday, April 1, 2017. The eighth annual awards event is called People with Purpose: A Pink Tie Gala. The awards recognize individuals and organizations whose work supports breast cancer survivors and the foundation’s programs. The gala dinner takes place April 1 from 6:00 p.m. to 10:00 p.m. at the Castlewood Country Club in Pleasanton, California. More information about the event, as well as online ticket sales, can be found at: http://hersbreastcancerfoundation.org/people-with-purpose. The event, held at a historic hilltop site in a ballroom with sweeping views of the valley, features a cocktail hour, charity auction, three-course dinner, award presentation, and dance to celebrate breast cancer survivors. KTVU’s Heather Holmes will be master of ceremonies. The funds raised will go toward HERS Breast Cancer Foundation programs, including “We Support, YOU Survive” which serves low-income women in need of post-surgical garments including bras and prostheses. The funds will also support the organization’s Lymphedema Project, which provides specialty garments for the prevention and ancillary treatment of the painful condition. HERS Breast Cancer Foundation assists clients with insurance claims and provides free products when needed. Funds are being raised through corporate sponsorship, donations, auction proceeds, and ticket sales. This year’s honorees include: Friends of Faith, a nonprofit in Oakland that raises money for breast cancer organizations; Denise Estrada, manager of Women’s Imaging and Cancer Services at Stanford Health Care ValleyCare in Pleasanton; Dr. Paul Wotowic, plastic surgeon at San Ramon Regional Medical Center, and Janice Florence, longtime volunteer at HERS. Friends of Faith, an Oakland-based nonprofit, provides information and financial support to organizations helping low income, underinsured women (and men) undergoing treatment for breast cancer. Faith Fancher was a journalist and highly visible Bay Area personality. When she was diagnosed with breast cancer in 1997, she turned her private battle with breast cancer into a public forum to raise awareness about the disease. Fancher worked to raise money for grassroots programs benefiting low-income women with breast cancer; the Friends of Faith organization is committed to continuing that work and following through on her vision. Denise Estrada, Manager of Women’s Imaging and Cancer Services at Stanford Health Care ValleyCare, has worked for 25 years to provide Tri-Valley cancer patients with high quality of care, leading multiple successful accreditation efforts for the Cancer Program. Estrada develops local community partnerships with cancer focused support programs and coordinates community outreach events to educate the community on breast health, latest treatments, and support services. Estrada is a dedicated supporter of HERS Breast Cancer Foundation and was instrumental in establishing the organization's program store in Pleasanton. Paul Wotowic, M.D. is a plastic surgeon at San Ramon Regional Medical Center. After serving as a medical officer in the U.S. Navy, Dr. Wotowic started a private practice in the Bay Area. He has active staff privileges at John Muir and San Ramon Region Medical Center where he served in leadership positions as Chief of Surgery and two terms as Chief of Staff. His training and practice reflects the full spectrum of plastic surgery including cosmetic, reconstructive, and nuanced areas of pediatric plastic surgery and facial reconstruction; he is board certified in both plastic surgery and otolaryngology. Dr. Wotowic understands the effects breast cancer surgeries have on a woman’s body and self-image and takes a holistic approach to helping survivors feel whole and beautiful again, a philosophy that aligns closely with the HERS Breast Cancer Foundation’s mission. Janice Florence is a longtime volunteer and supporter of HERS Breast Cancer Foundation. A San Jose native, Florence raised a family in the Bay Area and volunteered in school and community organizations. She worked for many years at the Child Abuse Prevention Agency. Upon retiring, she learned about HERS and volunteered to assist with the foundation’s outreach efforts. She puts her presentation skills to good use at health fairs and cancer conferences, and enjoys speaking with survivors. Florence is inspired by memories of her mother, who was profoundly affected by breast cancer and struggled to find proper fitting garments and prostheses after her treatment. The award being presented to Florence has been renamed the Harriet Despeaux Award in memory of another longtime HERS supporter and friend. Tickets for the People with Purpose: Pink Tie Gala may be purchased online at: http://hersbreastcancerfoundation.org/people-with-purpose/. About HERS Breast Cancer Foundation HERS Breast Cancer Foundation believes in restoring beauty and dignity to breast cancer survivors at an extremely vulnerable time of their lives. Every day we bring hope, empowerment, renewal and support, because every woman deserves to look and feel whole. We support all women healing from breast cancer by providing post-surgical products and services regardless of financial status. HERS is the only nonprofit organization in the Bay Area that provides appropriate products (such as bras, prostheses, lymphedema garments, and wigs) for breast cancer survivors in a safe, comfortable, and understanding environment. HERS Breast Cancer Foundation’s services for breast cancer survivors are provided at three locations: program stores at Stanford Health Care ValleyCare in Pleasanton and at the Stanford Cancer Center in Palo Alto, as well as their flagship program store at Washington Hospital in Fremont.
PubMed | Cancer Services
Type: Journal Article | Journal: British journal of nursing (Mark Allen Publishing) | Year: 2010
Urinary incontinence on its own is not considered life-threatening, yet it has been shown to negatively affect a patients wellbeing. While it is considered a common problem, with approximately 3 million women in the UK affected, the number of those women seeking help is much lower. This article will explore the relationship between urinary incontinence, quality of life (QoL), and barriers to help-seeking behaviour. Developing an understanding of this patient group will highlight implications for nursing practice. A number of factors appear to contribute to how women experience urinary incontinence, and how it impacts on QoL. While not all of these can be fully explored, the predominant factors appear to be: severity of urinary incontinence; type of urinary incontinence; age; and the actual QoL score itself. QoL scores are significant when women decide whether or not to seek help for urinary incontinence. Seeking help often depends on beliefs and an understanding of how the condition can be treated. Health promotion, the training of health professionals, and further research are required to improve the understanding of womens experiences, and to develop appropriate services with which to manage this condition.